» Articles » PMID: 3861856

Hypoxia Releases a Vasoconstrictor Substance from the Canine Vascular Endothelium

Overview
Journal J Physiol
Specialty Physiology
Date 1985 Jul 1
PMID 3861856
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Experiments were designed to determine the role of the endothelium in the facilitation by anoxia of contractile responses of isolated coronary arteries. Rings and strips of canine coronary arteries, with or without endothelium, were suspended for isometric tension recording in modified Krebs-Ringer bicarbonate solution. To determine the release of a vasoactive substance(s) from the endothelial cells, strips without endothelium were layered with strips containing endothelium. In rings and in layered preparations with endothelium, anoxia (95% N2-5% CO2) augmented contractile responses to prostaglandin F2 alpha. Hypoxia (10 or 5% O2) caused contractions in the presence of indomethacin. Removal of the endothelium abolished the anoxic facilitation, and the hypoxic contractions. Inhibitors of cyclo-oxygenase, lipoxygenase or phospholipase A2 or of adrenergic, serotonergic and histaminergic receptors did not prevent the response to anoxia. Likewise, inhibitors of the endothelium-derived factor(s) (quinacrine, phenidone and methylene blue) did not affect the anoxic facilitation. Hypoxia and anoxia caused contraction of coronary arteries without endothelium when layered with femoral arteries and veins with endothelium. Anoxic facilitation was observed in femoral arteries, but not in femoral veins, with endothelium. These experiments indicate that hypoxia and anoxia cause the release of a diffusible vasoconstrictor substance(s) from endothelial cells. The sensitivity of smooth muscle of different anatomical origin to the facilitatory mediator(s) varies.

Citing Articles

C-Terminal-Pro-Endothelin-1 Adds Incremental Prognostic Value for Risk Stratification After Ischemic Stroke.

Westphal L, Schweizer J, Fluri F, De Marchis G, Christ-Crain M, Luft A Front Neurol. 2021; 11:629151.

PMID: 33584523 PMC: 7873365. DOI: 10.3389/fneur.2020.629151.


Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19.

Das G, Das T, Chowdhury N, Chatterjee D, Bagchi A, Ghosh Z Genomics. 2020; 113(1 Pt 2):1129-1140.

PMID: 33189776 PMC: 7661923. DOI: 10.1016/j.ygeno.2020.11.009.


On a Magical Mystery Tour with 8-Bromo-Cyclic ADP-Ribose: From All-or-None Block to Nanojunctions and the Cell-Wide Web.

Mark Evans A Molecules. 2020; 25(20).

PMID: 33081414 PMC: 7587525. DOI: 10.3390/molecules25204768.


The Local Regulation of Vascular Function: From an Inside-Outside to an Outside-Inside Model.

Nava E, Llorens S Front Physiol. 2019; 10:729.

PMID: 31244683 PMC: 6581701. DOI: 10.3389/fphys.2019.00729.


Nitric Oxide: From Good to Bad.

Vanhoutte P Ann Vasc Dis. 2018; 11(1):41-51.

PMID: 29682106 PMC: 5882356. DOI: 10.3400/avd.ra.17-00134.


References
1.
Vanhoutte P . Effects of anoxia and glucose depletion on isolated veins of the dog. Am J Physiol. 1976; 230(5):1261-8. DOI: 10.1152/ajplegacy.1976.230.5.1261. View

2.
Rubanyi G, Vanhoutte P . Inhibitors of prostaglandin synthesis augment beta-adrenergic responsiveness in canine coronary arteries. Circ Res. 1985; 56(1):117-25. DOI: 10.1161/01.res.56.1.117. View

3.
Moncada S, Herman A, Higgs E, Vane J . Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977; 11(3):323-44. DOI: 10.1016/0049-3848(77)90185-2. View

4.
Macintyre D, Pearson J, Gordon J . Localisation and stimulation of prostacyclin production in vascular cells. Nature. 1978; 271(5645):549-51. DOI: 10.1038/271549a0. View

5.
Van Neuten J, van Beek J, Vanhoutte P . Inhibitory effect of lidoflazine on contractions of isolated canine coronary arteries caused by norepinephrine, 5-hydroxytryptamine, high potassium, anoxia and ergonovine maleate. J Pharmacol Exp Ther. 1980; 213(1):179-87. View